SEATTLE, Aug. 1, 2012 /PRNewswire/ -- Genelex Corporation today announced the acceptance of US Patent 8,099,298 titled, "Genetic Data Analysis and Database Tools." Genelex's patent, filed in early 2007, covers a variety of innovations for genetic analysis and interpretation, personalized prescribing, electronic medical records processing, and online reimbursement.
Notably covered are the algorithms which analyze and interpret patient specific pharmacogenetic and pharmacological information. These algorithms provide actionable insight into drug-drug and drug-gene interactions and are the backbone of comprehensive medication management reports and recommendations. These sophisticated software tools enable selection at the point-of-care of the safest and most effective drug and dose combinations for patients.
"The USPTO's issuance of this patent further demonstrates our leadership position in the rapidly growing Pharmacogenetics marketplace," stated Howard Coleman, Chief Executive Officer of Genelex. "Everyday prescribers call on us to help prevent and reduce adverse drug events improving and saving patient's lives and saving healthcare dollars."
Genelex has additional patents pending and continues to strengthen its Pharmacogenetics intellectual property and business model leadership.
Headquartered in Seattle, Genelex provides advanced decision support tools and genetic tests that help healthcare providers choose the safest, most effective medication regimens for their patients. Our personalized prescribing system takes the guesswork out of medication management and can reduce the incidence of adverse drug events, saving lives and healthcare dollars. For more information, please visit www.genelex.com.
SOURCE Genelex Corporation